NCT06295549View on ClinicalTrials.gov

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 11, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

LUCAR-G39P cells product

LUCAR-G39P cells product Prior to infusion of the LUCAR-G39P, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine

Trial Locations (3)

102206

RECRUITING

Beijing Gobroad Hosptial, Beijing

210029

RECRUITING

Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin

226001

RECRUITING

Affiliated Hospital of Nantong University, Nantong

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER